Edition:
United Kingdom

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

13.88USD
20 Apr 2018
Change (% chg)

$0.13 (+0.95%)
Prev Close
$13.75
Open
$13.96
Day's High
$14.25
Day's Low
$13.81
Volume
14,260
Avg. Vol
15,377
52-wk High
$16.59
52-wk Low
$8.80

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  SMMT.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -- -- --
ROI: -- 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Summit Therapeutics Says Proposed Placing To Raise Up To 15 Mln Stg

* ‍ANNOUNCES A PROPOSED PLACING TO RAISE UP TO £15.0 MILLION​

27 Mar 2018

BRIEF-Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics With Potential In Global Fight Against Gonorrhoea

* SUMMIT’S INFECTIOUS DISEASES TECHNOLOGY PLATFORM YIELDS NOVEL ANTIBIOTICS WITH POTENTIAL IN GLOBAL FIGHT AGAINST GONORRHOEA

13 Mar 2018

BRIEF-Summit Expands Enrolment In Phaseout DMD Phase 2 Clinical Trial To Include Planned Additional Group

* SUMMIT EXPANDS ENROLMENT IN PHASEOUT DMD PHASE 2 CLINICAL TRIAL TO INCLUDE PLANNED ADDITIONAL GROUP Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid

* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT’S PHASEOUT DMD CLINICAL TRIAL

25 Jan 2018

BRIEF-Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios

* SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA

21 Dec 2017

Earnings vs. Estimates

No consensus analysis data available.